Back

Ultrasound-guided bleomycin sclerotherapy for Warthin's tumor: preliminary results of a prospective study

Castren, E.; Sirviö, M.; Aro, K.; Lappalainen, K.; Linden, R.; Kurdo, G.; Tarkkanen, J.; Mäkitie, A.; Atula, T. S.

2023-09-01 otolaryngology
10.1101/2023.08.30.23294824 medRxiv
Show abstract

BackgroundWarthins tumor (WT) is the second most common parotid gland neoplasm with rising incidence. As some WT patients are not suitable for surgery, non-surgical treatment options are needed. This is the first study to evaluate the feasibility of ultrasound-guided bleomycin sclerotherapy (UGBS) for WT. Patients and methodsWT patients with concordant clinical, imaging, and cytology data were included. UGBS was proposed for patients who desired non-surgical intervention and fulfilled the inclusion criteria. Tumor volume and tumor-related symptoms were registered before UGBS and six months after. ResultsNine patients underwent UGBS between September 2021 and September 2022. In seven of the nine patients (78%), the tumor volume had diminished on average by 34% at six-month follow-up. Also, tumor-related pain, and cosmetic and functional discomfort decreased during the follow-up. One patient was later referred to partial parotidectomy. ConclusionUGBS could be an alternative non-surgical treatment for WT, especially for patients with risk factors for surgery.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.